Archive for the ‘Research News’ Category
Friday, October 31st, 2008
<< www.akelapharma.com<http://www.akelapharma.com> Toronto Stock Exchange Symbol: AKL >>MONTREAL, Oct. 30 /CNW Telbec/ - Akela Pharma Inc. (TSX: "AKL"), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that it has achieved the second of a series of three Fentanyl TAIFUN(R) Phase 3 study ...
Posted in Research News | No Comments »
Friday, October 31st, 2008
"We've had the privilege of using an early prototype of the Parallel Fixed Bed Reactor from Symyx Technologies at the Instituto Mexicano del Petroleo (IMP) Combinatorial Catalysis Laboratory," said Dr. J.A. Montoya, Director of the Combinatorial Catalysis Laboratory at IMP. "The Parallel Fixed Bed Reactor has been successfully applied for ...
Posted in Research News | No Comments »
Friday, October 31st, 2008
NEW YORK, Oct. 29, 2008 -- With unparalleled technical features, the XP56 microbalance tackles a typical problem of development and quality-control labs: With its minimum sample size and simple sample transfer procedure directly to a large tare container, the XP56 considerably reduces the use of expensive control substances. Control substances are ...
Posted in Research News | No Comments »
Friday, October 31st, 2008
PARIS, Oct. 29, 2008 - ExonHit Therapeutics S.A. (Alternext: ALEHT), a drug and diagnostic discovery company, today announces the publication of five new key scientific articles based on the use of its owned designed microarrays, SpliceArray™.“We are excited that the use of ExonHit's microarrays (SpliceArrayTM family of products) manufactured on ...
Posted in Research News | No Comments »
Thursday, October 30th, 2008
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Oct 30, 2008 - Bayhill Therapeutics, Inc., a leading developer of therapies for autoimmune diseases, and the Juvenile Diabetes Research Foundation, the world's leading charitable funder of type 1 diabetes research, today announced a partnership to support Bayhill's ongoing Phase I/II human clinical trial ...
Posted in Research News | No Comments »
Thursday, October 30th, 2008
DUBLIN, Ireland--(BUSINESS WIRE)--Oct 30, 2008 - Research and Markets (http://www.researchandmarkets.com/research/04db90/competitor_analysi) has announced the addition of the "Competitor Analysis: Insulin" report to their offering.This Competitive Intelligence report on insulin provides a competitor analysis in the development pipeline of novel insulin-based products for treatment of type 1 and 2 diabetes. The report ...
Posted in Research News | No Comments »
Thursday, October 30th, 2008
NEW YORK--(BUSINESS WIRE)--Oct 30, 2008 - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue.Protein Drugs: Global Markets and Manufacturing Technologieshttp://www.reportlinker.com/p096591/Protein-Drugs-Global-Markets -and-Manufacturing-Technologies.html(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra ...
Posted in Research News | No Comments »
Thursday, October 30th, 2008
PENZBERG, Germany--(BUSINESS WIRE)--Oct 30, 2008 - The xCELLigence Real-Time Cell Analyzer (RTCA) System from Roche Applied Science utilizes impedance read-out to noninvasively quantify cellular status in real-time. Several cell-based applications have been developed for the xCELLigence System so far. Among them are cellular quality control, cell proliferation or cytotoxicity. In ...
Posted in Research News | No Comments »
Thursday, October 30th, 2008
BILTHOVEN and AMSTERDAM, The Netherlands, October 30, 2008 /PRNewswire/ -- InteRNA Technologies B.V. and VU university medical center in Amsterdam, VUmc, announce today the signing of a framework research agreement to develop microRNA (miRNA)-based diagnostics and therapeutics for cancer using InteRNA's proprietary library of miRNAs.Under the research collaboration, InteRNA will ...
Posted in Research News | No Comments »
Thursday, October 30th, 2008
MILFORD, Mass.--(BUSINESS WIRE)--Oct 30, 2008 - SeraCare Life Sciences, Inc. (NASDAQ: SRLS) launched the Company's anticipated genetic controls business with the introduction of two new products at the Association for Molecular Pathology 2008 Annual Meeting. Initial products launched include ACCURUN(R) 601 controls for diagnostic testing of warfarin sensitivity and ACCURUN(R) ...
Posted in Research News | No Comments »
Thursday, October 30th, 2008
Evotec Earns Two Milestone Payments from Boehringer Ingelheim- First compound advanced into Preclinical Development -Hamburg, Germany, Oct. 30, 2008 - Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today announced that two further research milestones, leading to total payments to Evotec of EUR 6.0 million, have been successfully achieved in its drug ...
Posted in Research News | No Comments »
Thursday, October 30th, 2008
Sigma's Imprint(TM) Methylated DNA Quantification Kit significantly simplifies the study of Global Methylation with results in half the time of current methodsST. LOUIS, October 30, 2008 /PRNewswire-FirstCall/ -- Sigma-Aldrich today introduced its Imprint(TM) Methylated DNA Quantification Kit (MDQ1) for epigenetic research http://www.sigma-aldrich.com/mdq1. The Methylated DNA Quantification Kit employs a familiar ...
Posted in Research News | No Comments »
Thursday, October 30th, 2008
Hørsholm, Denmark, October 30, 2008-Summary: Pharmexa and KAEL Co. Ltd. of South Korea have entered into an agreement regarding GV1001 and Pharmexa´s Norwegian subsidiary Gemvax. Kael will acquire all shares of Gemvax and will thus assume all rights and responsibilities relating to the patent portfolio of GemVax including GV1001. In ...
Posted in Research News | No Comments »
Thursday, October 30th, 2008
SAN MARINO, Calif., October 29, 2008 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in Manhattan, New York. Rexin-G is the world's first tumor-targeted genetic medicine that is designed to seek out and destroy both primary tumors ...
Posted in Research News | No Comments »
Thursday, October 30th, 2008
- Sale Reinforces Strategic Focus and Enhances Cash Position -HOPKINTON, Mass., October 29, 2008 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. , a leading provider of tools and services for drug discovery and life sciences research, today announced that it has reached an agreement to sell its Pharmaceutical Development & Quality ...
Posted in Research News | No Comments »
